JP2024051082A5 - - Google Patents

Download PDF

Info

Publication number
JP2024051082A5
JP2024051082A5 JP2024027527A JP2024027527A JP2024051082A5 JP 2024051082 A5 JP2024051082 A5 JP 2024051082A5 JP 2024027527 A JP2024027527 A JP 2024027527A JP 2024027527 A JP2024027527 A JP 2024027527A JP 2024051082 A5 JP2024051082 A5 JP 2024051082A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
region
capsid polypeptide
aav2 capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024027527A
Other languages
English (en)
Japanese (ja)
Other versions
JP7741575B2 (ja
JP2024051082A (ja
Filing date
Publication date
Priority claimed from JP2020564154A external-priority patent/JP2021522840A/ja
Application filed filed Critical
Publication of JP2024051082A publication Critical patent/JP2024051082A/ja
Publication of JP2024051082A5 publication Critical patent/JP2024051082A5/ja
Application granted granted Critical
Publication of JP7741575B2 publication Critical patent/JP7741575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024027527A 2018-05-15 2024-02-27 改善された遺伝子送達特性を示すウイルスベクター Active JP7741575B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671949P 2018-05-15 2018-05-15
US62/671,949 2018-05-15
JP2020564154A JP2021522840A (ja) 2018-05-15 2019-05-08 改善された遺伝子送達特性を示すウイルスベクター
PCT/US2019/031307 WO2019221992A1 (en) 2018-05-15 2019-05-08 Viral vectors exhibiting improved gene delivery properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020564154A Division JP2021522840A (ja) 2018-05-15 2019-05-08 改善された遺伝子送達特性を示すウイルスベクター

Publications (3)

Publication Number Publication Date
JP2024051082A JP2024051082A (ja) 2024-04-10
JP2024051082A5 true JP2024051082A5 (enExample) 2024-04-19
JP7741575B2 JP7741575B2 (ja) 2025-09-18

Family

ID=68540740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564154A Withdrawn JP2021522840A (ja) 2018-05-15 2019-05-08 改善された遺伝子送達特性を示すウイルスベクター
JP2024027527A Active JP7741575B2 (ja) 2018-05-15 2024-02-27 改善された遺伝子送達特性を示すウイルスベクター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020564154A Withdrawn JP2021522840A (ja) 2018-05-15 2019-05-08 改善された遺伝子送達特性を示すウイルスベクター

Country Status (6)

Country Link
US (1) US12338267B2 (enExample)
EP (1) EP3813845A4 (enExample)
JP (2) JP2021522840A (enExample)
AU (1) AU2019270900A1 (enExample)
CA (1) CA3100066A1 (enExample)
WO (1) WO2019221992A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461836A1 (en) * 2017-09-28 2019-04-03 Universität zu Köln Mutated adeno-associated viral capsid proteins for chemical coupling of ligands, nanoparticles or drugs via thioether binding and production method thereof
IL293397A (en) * 2019-12-04 2022-07-01 Sangamo Therapeutics Inc New preparations and methods for the production of recombinant aav
US20210261625A1 (en) * 2020-01-29 2021-08-26 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111349148A (zh) * 2020-03-13 2020-06-30 辉大(上海)生物科技有限公司 一种腺相关病毒载体及其用途
AU2021264081A1 (en) * 2020-05-01 2022-11-03 Trustees Of Boston College Controlled modification of Adeno-Associated Virus (AAV) for enhanced gene therapy
AU2022296534A1 (en) * 2021-06-23 2024-01-25 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2023283962A1 (en) * 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
AU2022358779A1 (en) 2021-10-08 2024-04-18 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US20250352671A1 (en) * 2022-04-15 2025-11-20 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
EP4508065A2 (en) * 2022-04-15 2025-02-19 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US12480098B1 (en) * 2024-10-18 2025-11-25 Aavatar Therapeutics Co., Ltd. Adeno-associated virus variant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CA2373110A1 (en) 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP3492596A1 (en) * 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US20090215879A1 (en) * 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
JP6385920B2 (ja) * 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
PE20170260A1 (es) * 2014-05-02 2017-04-12 Genzyme Corp Vectores de aav para la terapia genica de la retina y el snc
US11124546B2 (en) 2015-12-14 2021-09-21 The University Of North Carolina At Chapel Hill Modified capsid proteins for enhanced delivery of parvovirus vectors
US20190071681A1 (en) * 2016-02-26 2019-03-07 University Of Florida Research Foundation, Incorporated Aav heparin mutants that display significantly improved eye and brain transduction

Similar Documents

Publication Publication Date Title
JP2024051082A5 (enExample)
KR100379569B1 (ko) 개기원의아데노바이러스벡터및유전자치료에서이의사용방법
JP5097714B2 (ja) Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
JP2023134488A5 (enExample)
JP2023068051A5 (enExample)
JP2024180560A5 (enExample)
CA2343653A1 (en) Recombinant newcastle disease virus rna expression systems and vaccines
CN111218477B (zh) 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用
US10851359B2 (en) Anti-tumor medicament based on adenovirus
CN101517079A (zh) 非复制型副粘病毒科病毒载体
JPWO2020218419A5 (enExample)
JP2004501646A5 (enExample)
WO2004106360A3 (en) Viral vectors with improved properties
JP2007530004A (ja) 疾患を処置するためのサブグループｂアデノウイルスベクター
JPWO2022119871A5 (enExample)
CN117448284B (zh) 一种稳定传代的表达egfp的重组坦布苏病毒及构建方法
WO2001092299A9 (en) Adenovirus particles with mutagenized fiber proteins
CN117646032B (zh) Bhv-1的反向遗传操作系统及其在病毒拯救中的应用
CN117025675A (zh) 一种提高Admax重组腺病毒包装系统的外源基因表达量的方法及应用
CN118547012B (zh) 一种SARS-CoV-2 S病毒样颗粒递送系统及其应用
WO2025065890A1 (zh) 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
US7264818B2 (en) BAV packaging regions and E1 transcriptional control regions
US20020137213A1 (en) Adenovirus particles with mutagenized fiber proteins
WO2023210616A1 (ja) Ｒｎａウイルス由来のキメラエンベロープタンパク質及び該タンパク質を持つｒｎａウイルスベクター
Brown Reovirus M1 gene expression